AU2006329836A1 - Compositions and methods for treating obesity and related metabolic disorders - Google Patents

Compositions and methods for treating obesity and related metabolic disorders Download PDF

Info

Publication number
AU2006329836A1
AU2006329836A1 AU2006329836A AU2006329836A AU2006329836A1 AU 2006329836 A1 AU2006329836 A1 AU 2006329836A1 AU 2006329836 A AU2006329836 A AU 2006329836A AU 2006329836 A AU2006329836 A AU 2006329836A AU 2006329836 A1 AU2006329836 A1 AU 2006329836A1
Authority
AU
Australia
Prior art keywords
peptide
polypeptide
des
nmx
fnx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006329836A
Other languages
English (en)
Inventor
Sarah L. Mcquaid
Richard Pittner
Ved Srivastava
Andrew A. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Publication of AU2006329836A1 publication Critical patent/AU2006329836A1/en
Assigned to AMYLIN PHARMACEUTICALS, LLC, ASTRA ZENECA PHARMACEUTICALS LP reassignment AMYLIN PHARMACEUTICALS, LLC Request for Assignment Assignors: AMYLIN PHARMACEUTICALS, INC.
Assigned to ASTRA ZENECA PHARMACEUTICALS LP reassignment ASTRA ZENECA PHARMACEUTICALS LP Request for Assignment Assignors: AMYLIN PHARMACEUTICALS, LLC, ASTRA ZENECA PHARMACEUTICALS LP
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2006329836A 2005-12-16 2006-12-15 Compositions and methods for treating obesity and related metabolic disorders Abandoned AU2006329836A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75141205P 2005-12-16 2005-12-16
US60/751,412 2005-12-16
PCT/US2006/047953 WO2007075439A2 (en) 2005-12-16 2006-12-15 Compositions and methods for treating obesity and related metabolic disorders

Publications (1)

Publication Number Publication Date
AU2006329836A1 true AU2006329836A1 (en) 2007-07-05

Family

ID=38218466

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006329836A Abandoned AU2006329836A1 (en) 2005-12-16 2006-12-15 Compositions and methods for treating obesity and related metabolic disorders

Country Status (6)

Country Link
US (1) US20090209460A1 (enExample)
EP (1) EP1973953A2 (enExample)
JP (1) JP2009519949A (enExample)
AU (1) AU2006329836A1 (enExample)
CA (1) CA2634016A1 (enExample)
WO (1) WO2007075439A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009040020A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
US20100184698A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of a deslorelin and mastoparan as a therapeutic agent
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN102459311B (zh) * 2009-04-08 2015-08-19 武田药品工业株式会社 神经调节肽u衍生物
PL2427475T3 (pl) * 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
JP2013209295A (ja) 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2018175924A1 (en) 2017-03-24 2018-09-27 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
US20240279278A1 (en) 2023-01-12 2024-08-22 Boehringer Ingelheim International Gmbh Nmu receptor 2 agonists
WO2026013210A1 (en) 2024-07-11 2026-01-15 Boehringer Ingelheim International Gmbh Novel nmu receptor 2 agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081418A1 (en) * 2000-04-27 2001-11-01 Merck & Co., Inc. New neuromedin u receptor nmur2 and nucleotides encoding it
JP2002265497A (ja) * 2001-03-12 2002-09-18 Tadashi Hashimoto 生理活性ペプチドニューロメジンｕの高活性誘導体
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2592201C (en) * 2004-12-24 2016-08-09 Japan As Represented By The President Of National Cardiovascular Center Neuromedin s and the use thereof
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
WO2008097536A2 (en) * 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders

Also Published As

Publication number Publication date
EP1973953A2 (en) 2008-10-01
WO2007075439A2 (en) 2007-07-05
WO2007075439A3 (en) 2007-12-06
CA2634016A1 (en) 2007-07-05
JP2009519949A (ja) 2009-05-21
US20090209460A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
US20090209460A1 (en) Compositions and methods for treating obesity and related metabolic disorders
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
RU2427586C2 (ru) Мотивы семейства панкреатических полипептидов, полипептиды и способы их использования
US10005824B2 (en) Selective PYY compounds and uses thereof
AU2006230420B2 (en) Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
US9085637B2 (en) Selective PYY compounds and uses thereof
US20190256569A1 (en) Gip agonist compounds and methods
JP5743371B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
US8022035B2 (en) Y4 selective receptor agonists for therapeutic interventions
AU2008257448B9 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US20080269114A1 (en) Y4 Selective Receptor Agonists For Thereapeutic Interventions
CN1551780A (zh) 用于预防或治疗体重过重的胃肠激素
US11713344B2 (en) Acylated oxyntomodulin peptide analog
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
CN104395338A (zh) 人胰岛淀粉样多肽类似物
JP2020500890A (ja) Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
CN102174115A (zh) 具有可选择特性的杂合多肽
US7928060B2 (en) Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
WO2023139106A2 (en) Long-acting gipr antagonists
US12139520B2 (en) HAM15-52 analogues with improved amylin receptor (hAMY3R) potency
AU2007269622A1 (en) Glucagon-like peptides and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
PC1 Assignment before grant (sect. 113)

Owner name: ASTRA ZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUT

Free format text: FORMER APPLICANT(S): AMYLIN PHARMACEUTICALS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: ASTRA ZENECA PHARMACEUTICALS LP

Free format text: FORMER APPLICANT(S): AMYLIN PHARMACEUTICALS, LLC; ASTRA ZENECA PHARMACEUTICALS LP

TH Corrigenda

Free format text: IN VOL 27 , NO 5 , PAGE(S) 692 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2006 UNDERTHE NAME ASTRA ZENECA PHARMACEUTICALS LP, APPLICATION NO. 2006329836, UNDER INID (71), CORRECT THE NAME TO ASTRAZENECA PHARMACEUTICALS AND AMYLIN PHARMACEUTICALS, LLC.